OPTIVIA BIOTECHNOLOGY AND RHENOVIA PHARMA SIGN A PARTNERSHIP AGREEMENT
Companies agree to partner to expand product and service offerings for better understanding drug’s effects in brain.
Menlo Park, CA, Mulhouse, France, Cambridge, MA (PRWEB) May 20, 2015 – Optivia Biotechnology, the leading provider of high quality transporter assay services for Drug-Drug Interactions (DDI), Metabolism and Pharmacokinetics (DMPK), Safety and Pharmacology, and Rhenovia Pharma, a world leader in assessing impact of drugs and mutations on neurotransmission using Translational Quantitative Systems Pharmacology supported by biosimulation, announced today that they have signed a partnership agreement.
The agreement allows both companies to expand their product and service offerings. The partnership will combine the use of Optivia’s Opti-CNS™ neuronal transporter profiling services with Rhenovia’s RHENOMS™ Nervous System (NS) Biosimulation Platform to improve data interpretation and gain a deeper understanding of the therapeutic and adverse effects of drugs in the brain.
Optivia’s President and CEO, Yong Huang, Ph.D., expressed his enthusiasm about the partnership. “Our focus is always to provide scientists with the right tools for the question at hand. Funded by two research grants from the National Institute of Mental Health (NIMH) and the US FDA, we are creating the largest database of interactions between drugs and neurotransmitter transporters that play critical roles in CNS (patho)physiology. Rhenovia’s biosimulation platform, which focuses on the nervous system in its entirety, adds significant value to that endeavor by enabling the development of a clearer picture on how such interactions lead to therapeutic or adverse effects in complex and intricate neurotransmission networks.”
“We are delighted to join our efforts with Optivia in providing our respective customers and partners this very unique service offering,” said Rhenovia’s President, Serge Bischoff, PhD. “The partnership enables our customers to screen drug candidates and active ingredients in Optivia’s broad transporter portfolio and profile hits and leads in Rhenovia’s biosimulators of nervous system functions and pathologies.”
The combination of the technologies allows Optivia’s and Rhenovia’s customers to better understand the mechanism of action and potential for adverse events in the complicated field of CNS drug development.
About Optivia Biotechnology
Since bringing the first full panel of FDA- and EMA-compliant transporter drug-drug interaction (DDI) assays to market, Optivia has been the leading provider of high-quality transporter assay services. Optivia is a thought leader in expanding the utility of transporter research in areas as diverse as pharmacokinetics, toxicology, therapeutic target discovery, and basic biology research. With the world’s largest portfolio of transporter assays, novel multi-transporter models, and customized molecular transport research solutions, Optivia is committed to understanding the complex drug transport processes for improving drug safety and efficacy.
About Rhenovia Pharma
Rhenovia Pharma SAS is a healthcare company founded in 2007 by an international team comprising executives from the pharmaceutical industry and world experts in neuroscience and computational modeling. The company specializes in biosimulation of the nervous system, a field in which it became the acknowledged world leader in less than 5 years. Rhenovia creates computer simulators, which replicate various features of the nervous system in healthy human, or pathological conditions (Alzheimer, Parkinson, epilepsy, schizophrenia, depression, etc.). These in silico simulators allow to predict the efficacy and toxicity of molecules or combinations of molecules without going through in vitro/in vivo laboratory experimentations. Rhenovia’s main fields of application are drug discovery, agri-food, as well as civil security and defense.
About Transporter Proteins
Transporters are a class of 300 to 400 membrane proteins that act as nature’s “gatekeepers,” facilitating the movement of drugs, nutrients, and other bioactive molecules into and out of cells. Through modulating drug absorption, distribution, metabolism and excretion (ADME) in the body, transporters play a vital role in drug response and safety, as testified by global regulatory requests on testing transporter mediated DDIs for preventing dangerous adverse drug events. Moreover, transporters can be therapeutic targets for various diseases such as Central Nervous System (CNS) disorders, cancer, and diabetes.